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Abstract 
 
In human and experimental myocardial infarction cessation of blood supply leads to rapid necrosis of 
cardiac myocytes in the ischemic heart. Immediately after injury various intra- and inter-cellular pathways 
contribute to healing the myocardial wound in order to achieve tissue integrity and function. Myocardial 
infarction  and  the  consequent  loss  of  myocardium  is  the  major  aetiology  for  heart  failure.  Despite 
aggressive  primary  therapy,  prognosis  remains  poor  in  patients  with  large  infarction  and  severe  left 
ventricular dysfunction. Thus, it would be highly desirable to improve healing of the cardiac wound to 
maintain structure and function of the heart. Healing in the heart occurs in overlapping phases. Herein, we 
review the inflammatory phase as a trigger of tissue formation.  
 
Keywords: Myocardial infarction; healing; inflammation 
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One  major  determinant  of  remodeling  post  myocardial  infarction  (MI)  is  infarct  size 
1.    Infarct  size 
depends on the amount of myocardium supplied by the infarct related coronary artery, the time to effective 
reperfusion therapy and myocardial energy consumption during coronary occlusion. Early reperfusion and 
beta-blocker are therefore standard therapy today. However, slow flow or no-reflow phenomena are quite 
frequent  post  MI  and  may  contribute  to  ongoing  ischemia.  After  reperfusion,  “the  infarct”  in  most 
instances will consist of highly inhomogeneous tissue which may immediately recover, be stunned or 
apoptotic/necrotic. Sensitivity against ischemia varies among myocardial cells, vasculature and connective 
tissue  adding  to  inhomogeneity  of  infarct  tissue  composition 
2.  In  addition,  inflammatory  cells  and 
macrophages may invade from circulating blood and start as well as maintain processes of inflammation, 
clearing  debris  and  wound  healing.  Toxic  or  protective  mediators,  circulating  and  locally  released  by 
autochthonous or recruited cells add to complexity.  It may be of major therapeutic value to influence 
myocardial  healing  since  it  opens  a  new  time  window  and  addresses  new  mechanisms  for  therapy. 
However, specific measures have not yet been developed mostly due to a lack of precise knowledge of 
processes  contributing  to  wound  healing.  The  present  review  (1)  puts  forward  the  hypothesis  that  a 
reperfused MI may be considered a healing wound, (2) compiles evidence for cells and factors controlling 
the inflammatory phase of wound healing, and (3) proposes potential anti-inflammatory mechanisms as 
tasks for therapeutic research.   
Myocardial Infarction a Healing Wound 
The capacity for regeneration and reperation certainly was of selection value in evolution and is highly 
variable  among  species.  Some  species  may  restore  organs  or  limbs  in  total;  mammalian  are  mostly 
restricted to reparation and varability is high among individual organs. Healing of external wounds is a 
conditio sine qua non for survival and therefore secured by multiple redundant mechanisms. Nevertheless 
it may vary substantially among individuals. There appear to be differences in wound healing in regard to 
sex, age and race while genetics of wound healing have not been clarified. A large body of empirical 
knowledge has been accumulated on measures to support wound healing. More recently, essential factors 
for wound healing  have been identified  but implications of such ”healing factors” for healing of internal 
wounds remain unclear. Two types of ”wounds” are particular frequent and highly clinically relevant in the 
cardiovascular system. Rupture of an atherosclerotic plaque and myocardial infarction. For the latter, if 
survived, healing is essential for further prognosis. Both of them are  modern diseases and thus evolution 
could not yet develop specific strategies by selection. Thus, general strategies of coping with stress and 
wound healing take place.  
The healing process may first be dominated by inflammation, that is degradation of extracellular matrix, 
inhibition of tissue proliferation and release of inflammatory mediators (”inflammatory phenotype”), and 
turn then to reparation, that is increased matrix synthesis, proliferation of fibroblasts and inflammatory 
cells, and release of fibrosis promoting cytokines leading to scar formation (”activated phenotype”). The 
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analysis of these processes may be of major therapeutic importance. Herein, we will focus on the early 
inflammatory phase as the trigger of tissue formation. 
The inflammatory phase of wound healing 
 
Triggers of inflammation after cardiac injury 
What is the trigger of an inflammatory reaction after cardiac injury? Indeed, activation of the 
immune  system  after  cardiac  injury  follows  the  pattern  of  immune  activation  after  infection:  Most 
microorganisms encountered daily by a healthy individual are detected and destroyed within hours by 
defense  mechanisms  that  are  not  antigen-specific, the  so  called  innate  immune  system. In contrast to 
adaptive  immunity,  whereby  specific  antigen  receptors  are  generated  by  somatic  hypermutation  and 
selection,  the  innate  immune  systems  uses  germline-encoded  proteins  that  recognize  specific  patterns 
shared by groups of pathogens, but not the host. These receptors, called “pattern recognition receptors”, 
detect largely invariant patterns, for example lipopolysaccharides of bacteria or double-stranded RNA of 
viruses 
3-5. They are constitutively expressed; thus, defense mechanisms are readily available and need not 
be  upregulated.  The  heart  itself  expresses  all  parts  of  the  innate  immune  system  including  pattern 
recognition receptors and effector proteins.  
Whereas  it  is  commonly  accepted  that  the  innate  immune  system  is  activated  by  microbial 
patterns, Matzinger assumes in the “Danger” model that the presence of potentially infectious patterns does 
not necessarily trigger an immune response unless there is evidence of host tissue injury by the so-called 
“alarm” signals. In support of this hypothesis, Matzinger and her colleagues 
6 have demonstrated that, in 
the absence of any foreign pathogens, resting dendritic cells can be activated by virally infected or necrotic 
cells, but not by healthy cells or cells undergoing programmed cell death (apoptosis). Potential mediators 
include reactive oxygen species (ROS), heat shock proteins, and fibronectin 
7. Thus, this work suggests 
that certain products of tissue injury, like ROS and intracellular proteins released from necrotic cells, 
initiate an inflammatory response leading to the activation of pattern recognition receptors like Toll like 
receptors, the transcription factor nuclear factor kappa B (NF-κB) and complement. 
 
Toll like receptors 
Toll like receptors (TLRs) have emerged as the primary, non-antigen-specific defense mechanisms 
that enable innate immune detection of foreign pathogens and rapid anti-pathogen defense mechanisms. 
Thus, TLRs could be important for the initiation of the inflammatory phase after tissue injury. 
To date, 11 human and 13 mouse TLRs have been cloned 
5. The ligands for TLRs are molecular 
motifs produced by pathogens, but also certain host derived proteins like HSP or fibronectin. As recently 
reviewed by us 
7, 8, TLR2, -3, -4, and -6 are expressed in cardiac myocytes, whereas TLR1 and -5 are not 
9, 
10. TLRs and  their signaling  components  are  activated in experimental or clinical  heart failure. TLR4 
expression is increased in the myocardium of patients with advanced heart failure 
10, 11. In addition, there is 
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a  change  in  the  TLR  expression  pattern:  Whereas  in  normal  murine  and  human  myocardium  TLR4 
expression is diffuse and predominantly confined to cardiac myocytes, myocardium from patients with 
advanced heart failure displays focal areas of intense TLR4 staining 
10 (see figure 1).  
The data on myocardial wound healing and TLRs is very limited: After coronary artery ligation, 
mortality and left ventricular dilatation were significantly reduced, left ventricular function was preserved 
in TLR2
-/- and TLR4
-/- mice 
12, 13. In ischemia/ reperfusion experiments the invasion of inflammatory cells 
as well as infarct size were significantly reduced in TLR4 KO animals 
14. Conclusively, the data suggests a 
role of TLRs for the activation of inflammatory cells after cardiac injury. 
 
Nuclear factor kappa B (NF-κB) 
TLR  signaling  converges  on the  activation  of  the  transcription factor  NF-κB,  a  key  signaling 
component  for  early  inflammatory  activation.  As  for  TLRs,  the  role  of  NF-κB  in  healing  can  only 
indirectly  be  deduced  from  heart  failure  as  well  as  ischemia/reperfusion  models.  NF-κB  dependent 
signaling  mechanisms  in  ischemia/  reperfusion  injury  are  well  defined  by  now 
15.  After 
ischemia/reperfusion injury, NF-κB activation is biphasic, with peaks after 15 minutes and 3 hours i.e. 
early in the healing process 
16, 17. As for TLR, ischemia/ reperfusion injury is reduced by inhibition of NF-
κB using molecular (inhibition of p65 by double-stranded oligonucleotides 
18, use of an IκB triple mutant 
(S32A, S36A, Y42A) completely abrogating NF-κB activation 
19), as well as pharmacological methods 
(IKK inhibition 
20). We recently demonstrated that mice with targeted deletion of the NF-κB subunit p50 
are  protected  against  ischemia/reperfusion  injury 
21.  KO  and  WT  animals  underwent  30  minutes  of 
coronary  artery  ligation  and  24  hours  of  reperfusion  in  vivo.  Ischemia-reperfusion  damage  was 
significantly attenuated in the p50 KO compared to WT mice. Although adhesion molecules such as ICAM 
were  upregulated  in  left  ventricles  of  p50  KO  animals,  fewer  neutrophils  infiltrated  the  infarct  area, 
suggesting  leukocytes  as  a  potential  mediator  of  the  protection  observed  in  the  p50  KO.  This  was 
confirmed in adoptive transfer experiments: Whereas transplantation of KO bone marrow in KO animals 
sustained the protective effect on ischemia-reperfusion injury, transplantation of WT bone marrow in KO 
animals abolished it. Thus impaired NF-κB activation in p50 KO leukocytes attenuated cardiac damage.  
After chronic coronary artery ligation, activation of NF-κB peaks after 3 days (see figure 2) 
22, 23. 
Mice with targeted deletion of the NF-κB subunit p50 are protected from left ventricular dilatation after 
myocardial  infarction  and  have  preserved  left  ventricular  function.  Collagen  content  and 
matrixmetalloproteinase  (MMP)-9  expression  are  significantly  lower  in  KO  mice  after  myocardial 
infarction and may account for improved left ventricular remodeling 
24.  
Thus, NF-κB is important for activation of inflammation and healing after myocardial infarction. 
The effects on healing seem to be cell type specific. 
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Complement 
The  complement  system  is  central  to  the  innate  immune  system.  It  can  be  activated  via  the 
classical, alternative, and lectin pathway. Complement has long been implicated in mediating tissue injury 
in  ischemic  organs, with  or  without reperfusion 
25-28.   Activation  of  complement is  an  early  event in 
ischemia/reperfusion  injury  and  healing,  although  the  mechanism(s)  leading  to  complement  activation 
have  only  recently  been  identified.    Carroll  and  his  colleagues 
28,  29  have  demonstrated  that  selective 
depletion  of  natural  IgM  is  sufficient  to  abrogate  most  ischemic-reperfusion  injury  in  both  murine 
hindlimb 
28 or murine intestinal 
29 reperfusion injury models. The self-target for this monoclonal natural 
IgM is non-muscle myosin heavy chain type II A and C 
30. These data could also be reproduced for the 
heart 
31: Mice baring an altered natural IgM repertoire (Cr2
-/-) were protected from ischemia/ reperfusion 
injury and had a reduction in inflammatory infiltrates. This effect could be blunted by IgM reconstitution 
suggesting that neoepitopes recognized by natural IgM appear on the surface of endothelium damaged by 
reperfusion injury. In conclusion, complement is activated and an important mediator of neutrophil and 
monocyte recruitment early after injury 
32.  
 
Oxidative Stress 
ROS are atoms or molecules with unpaired electrons in their outer orbit. ROS can directly react 
with lipids, proteins, and DNA causing cell injury and death. ROS can trigger cytokine and chemokine 
release partially mediated by NF-κB. Oxidative stress produces myocardial contractile dysfunction and 
structural  damage,  and  has  been  implicated  in  the  development  of  heart  failure  and  left  ventricular 
remodeling following myocardial infarction 
33-35. Indeed, cardiac tissue itself is a rich source of ROS, and 
NADPH  oxidases,  xanthine  oxidases  and  mitochondria  are  critical  determinants  of  myocardial  ROS 
generation 
36, 37.  
The normal heart possesses substantial ability to neutralize ROS, however in the injured heart the 
anti-oxidant defense is overwhelmed, resulting in generation of oxygen-related free radicals. Markers of 
oxidative stress are elevated after myocardial infarction 
38. Various antioxidant approaches reduce adverse 
cardiac remodeling 
39, e.g. overexpression of glutathione peroxidase 
40. Despite the damaging effects of 
oxidation  itself,  ROS  can  directly  influence  signaling.  E.g.  increased  ROS  production  promotes  the 
development of interstitial fibrosis and extracellular matrix turnover, in part through activation of matrix 
metalloproteinases. Thus, ROS are able to generate an inflammatory response of the healing phase by 
necrosis and redox signaling. 
In the clinical arena, the results of anti-oxidant therapy are discouraging: In the HOPE and Heart 
Protection study cardiovascular events were not improved by vitamin E treatment 
35. There are a number of 
reasons  why  vitamin E supplementation  had not  the  proposed effect:  usage  of  the  wrong antioxidant, 
necessity of other antioxidative cofactors, binding of vitamin E to the cell membrane while oxidative stress 
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is intracellularly generated and the problem that a single supplement may not be able to compensate for 
other coexisting abnormalities. Thus, the final role of anti-oxidant medication remains to be determined.  
 
Coagulation Cascade 
In the first stage of wound healing activation of the coagulation cascade is necessary to prevent 
ongoing blood and fluid loss. Hemostasis is achieved by the formation of a platelet plug, which becomes a 
scaffold for infiltrating cells. Several coagulation factors are able to activate an innate immune response: 
E.g. thrombin and Factor Xa promote cytokine and chemokines synthesis 
41. 
With respect to healing and inflammation after myocardial infarction, blood coagulation factor 
XIII (FXIII) has been most thoroughly investigated. It is activated by thrombin in the final stage of the 
clotting cascade. FXIII
-/- mice invariably die after myocardial infarction due to left ventricular rupture 
accompanied by reduced migration of neutrophils into the ischemic zone 
42. FXIII levels are decreased in 
patients  with  insufficient  healing  after  myocardial  infarction 
43.  Gene  variants  (L34)  increasing  FXIII 
activity are associated with improved survival after myocardial infarction 
44. The most likely source of 
FXIII in healing infracts are invading macrophages 
45.  
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Mediators of inflammation 
 
Upon  activation  of  the  innate  immune  system  by  the  ischemic  injury  several  inflammatory 
mediators are released and inflammatory cells are attracted to the site of injury. All of these humoral and 
cellular factors have distinct function for the healing process.  
Humoral immune response 
 
Cytokines 
A variety of cytokines are activated after myocardial infarction and implicated in healing. We will 
exemplify their role by focusing on interleukin (IL)-1β and tumor necrosis factor (TNF) in this review. 
Blood levels and/or myocardial expression levels of IL-1β are increased in patients with coronary 
artery  disease 
46,  acute  myocardial  infarction 
47,  in  patients  with  dilated  cardiomyopathy 
48,  49  and  in 
patients and animal models of congestive heart failure 
50.  There are two peaks of IL-1β expression after 
myocardial infarction in the rat: there is an initial rise in the healing phase, within 24 hr, that appeared on 
immunohistochemical  analysis  to  be  located  predominantly  in  the  microvascular  endothelium,  and  a 
second peak at 7 days with predominant staining of infiltrating macrophages in the infarct zone 
51.   
Despite these observations, there have been only a few reports about IL-1β function in ischemic 
heart  disease.  Indeed,  in  some  experimental  models,  early  administration  of  inflammatory  cytokines 
decreases myocardial injury.  Brown et al 
52, 53 observed protective effects of TNF and IL-1β in a model of 
ischemia/reperfusion injury. Pretreatment with IL-1β in an ischemia/reperfusion model in the isolated rat 
heart increased left ventricular developed pressure and decreased the area at risk 
54. In contrast, long term 
activation of cytokines seems to be detrimental: Mice lacking the active forms of IL-1β and IL-18 (i.e., a 
caspase-1  knockout  model)  exhibited  both  improved  peri-infarct  survival  and  decreased  ventricular 
dilatation after experimental myocardial infarction, possibly due in part to a decrease in MMP-3 (matrix 
metalloproteinase 3) activity and reduction of apoptosis 
55, 56. With respect to the healing phase, in IL-1 
receptor  KO  mice  myofibroblast  infiltration  and  collagen  deposition  were  decreased  as  was  the 
development of adverse left ventricular remodeling after experimental myocardial infarction 
57. Thus, IL-1 
signaling is essential for activation of inflammatory pathways in the healing infarct.  
The role of another innate immunity cytokine, TNF, has been extensively investigated after cardiac 
injury. In fact, TNF can mimic several symptoms of heart failure: Mice overexpressing TNF develop heart 
failure 
58,  59. Systemic infusions of recombinant TNF that yielded blood concentrations of TNF seen in 
patients  with  advanced  heart  failure  depressed  left  ventricular  function  and  caused  left  ventricular 
dilatation 
60.  Moreover, the expression of TNF mRNA and protein is elevated in patients and in animal 
models with advanced heart failure due to a number of different etiologies 
50, 61. Importantly, TNF has also 
a prognostic impact: TNF was elevated in a large portion of heart failure patients with preserved and 
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reduced ejection fraction and was associated with a large decrease in survival 
62.
 However, the function of 
TNF is much more complex than initially anticipated: Double knockout mice for the TNF receptor 1 and 2 
had larger infarct sizes and increased apoptosis after myocardial infarction indicating that TNF has also 
protective functions for the myocardium 
63.  
Chemokines 
Chemokines 
64 are small polypeptides synthesized by many cells of the immune system as well as 
by a number of non-immune cells including endothelial cells and keratinocytes. All chemokines are related 
in their amino acid sequences and function primarily as chemoattractants for phagocytic cells. Generally, 
CXC  chemokines,  such  as  RANTES,  promote  neutrophil  migration,  while  CC  chemokines,  such  as 
interleukin-8,  mediate  migration  of  monocytes  and  other  cell  types.  A  number  of  CXC  chemokines, 
including IL-8 and others, appear to play a role in mediating angiogenesis. Induction of chemokines occurs 
in  the  post-infarction  inflammatory  response 
65.  IL-8  is  a  critical  regulator  of  neutrophil  influx  in 
inflammatory  processes.  Inhibition  of  IL-8  in  a  rabbit  ischemia/  reperfusion  model  reduced  necrosis 
without altering inflammatory cell invasion 
66. However, the role of other chemokines in cardiac wound 
healing has not been intensively investigated so far. 
 
Cellular immune response 
 
Neutrophils  are  important  mediators  of  the  inflammatory  response.  They  release  oxidants  and 
proteases, secrete mediators for inflammatory cell recruitment, and phagocyte cell debris and dead cells.  
The recruitment of neutrophils to ischemic tissue requires neutrophil-endothelial interactions that 
are regulated by a cascade of molecular steps. After activation, leukocytes roll along postcapillary venules, 
change shape and extravasate in the tissue. The selectin family (E-, L-, P-selectin) of adhesion molecules 
mediates the initial capture of leukocytes. The importance of these proteins for healing is documented by 
the fact that E- and P-selectin knockout mice are protected from ischemia/ reperfusion injury and have 
reduced inflammatory cell infiltrates 
67, as are feline hearts treated with an antibody against L-selectin 
68. 
Selectin adhesion of leukocytes is not  very  tight.  Firm adhesion and transmigration  needs  the 
engagement of integrins. Integrins are a family of heterodimeric membrane glycoproteins. Consequently, 
integrin-related strategies have been used to mitigate ischemia/ reperfusion injury. Indeed, e.g. inhibition 
of integrin CD18 reduced infarct size 
67.   
Crude  depletion  of  neutrophils  itself  by  leukocyte  filters  reduces  infarct  size  in  ischemia 
reperfusion  models 
69  indicating  a  detrimental  role of  neutrophils  for  infarct  healing.  The  detrimental 
effects  seem  to  be  mediated  by  an  ICAM-1  dependent  neutrophil-cardiomyocyte  adhesion,  a  primary 
ligand of CD18 integrin. ICAM-1 KO mice have less myocardial injury early after myocardial infarction 
70. Neutrophils release various cytokines and growth factors important for healing. However, this effect is 
not essential for scar formation since depletion of neutrophils had no effect on granulation tissue formation 
in a cutaneous wound healing model 
71. It is especially problematic, that neutrophil effects vary depending 
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on the stage of activation. E.g. it seems that neutrophils release toxic products almost exclusively when 
adherent  to  vascular  wall,  but  not  when  they  have  evaded  in  the  tissue.  Thus,  although  multiple 
experiments suggest a central role of neutrophils in myocardial healing, the function of neutrophils remains 
unclear.  
Macrophages 
Healing of myocardial infarction requires monocytes/macrophages. The mononuclear phagocytes 
degrade  released  macromolecules  and  scavenge  dead  cardiomyocytes.  Infarcted  hearts  modulate  their 
chemokine expression profile over time, and they sequentially and actively recruit Ly-6C(hi) and -6C(lo) 
monocytes. Ly-6C(hi) monocytes dominate early and exhibit phagocytic, proteolytic, and inflammatory 
functions.  Ly-6C(lo)  monocytes  dominate  later.  Consequently,  Ly-6C(hi)  monocytes  digest  damaged 
tissue, whereas Ly-6C(lo) monocytes promote healing via myofibroblast accumulation, angiogenesis, and 
deposition of collagen 
72. Depletion of macrophages in a murine cryoinjury model impaired wound healing 
since  non-resorbed  cell  debris  could  not  be  discarded.  This  was  accompanied  by  increased  mortality. 
Macrophage accumulation in the healing heart are regulated by the renin-angiotensin-aldosterone system: 
Selective mineralocorticoide receptor blockade immediately after myocardial infarction improved healing 
(see figure 3), an effect that could be blunted by macrophage depletion 
45. Thus, macrophages are of 
central importance for adequate healing after myocardial infarction. 
 
Post-inflammation phase 
 
Following  the  initial  inflammatory  phase,  optimal  healing  requires  mechanisms  that  inhibit 
cytokine release, clear the inflammatory infiltrates, and initiate collagen production to institute a solid scar.  
Granulocytic infiltrates are cleared by phagocytes after granulocyte apoptosis 
65. In contrast to 
necrosis that triggers an inflammatory response, apoptotic cells lead to the production of anti-inflammatory 
cytokines  like  IL-10  and  TGF  (transforming  growth  factor)  initiating  the  transition  phase  from 
inflammation to fibrosis. 
TGF-β is a locally generated cytokine and of central importance for this transition phase 
73: TGF-β 
decreases leukocyte adhesion and stimulates fibroblast proliferation and extracellular matrix production 
74. 
TGF-β expression is increased in the ischemic as well as hypertrophied heart 
75, 76. TGF-β has an important 
function for healing after myocardial infarction: We demonstrated recently that anti-TGF-β treatment in 
the first days after coronary artery ligation increases mortality and worsens left ventricular remodeling in 
mice with myocardial infarction due to alterations of the extracellular matrix (see figure 4) 
77.  
A detailed review of the post-inflammation phase is beyond the scope of the present article due to 
space constraints. 
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How far is the translation of experimental inflammation/ healing data from present clinical arena? 
 
The  importance  of  inflammation  for  healing  processes  after  myocardial  infarction  has  been 
recognized for several years and pathophysiologic concepts have been established by experimental data. 
Consequently a transfer of this knowledge into standard clinical practice has been tried: Inflammatory 
markers have been used to predict mortality. Indeed, some inflammatory proteins (e.g. TNF) are associated 
with outcome, however they could not be established as standard clinical utility since other parameters 
turned  out  to be  more  powerful.  The  translation of  the  experimental  knowledge  into  new  therapeutic 
modalities turned out to be a difficult task. Several treatments have been tried after acute myocardial 
infarction:  
 
Complement  inhibitiors  have  been  evaluated  as  an  adjunctive  therapy  to  fibrinolysis  or 
percutaneous  coronary  intervention  (PCI)  in  acute  myocardial  infarction.  A  humanized  monoclonal 
antibody against complement component C5, pexelizumab, was used that specifically binds to C5 with 
high  affinity  and  prevents  cleavage  and  generation  of  activated  C5a  and  C5b-9.  However,  although 
pexelizumab had been previously shown to reduce infarct size and apoptosis in rats after ischemia and 
reperfusion 
78, it had no effect on mortality in patients treated with fibrinolysis (COMPLY trial 
79) or PCI 
(COMMA trial) 
80. 
In a multicenter, placebo controlled trial, patients undergoing PCI for acute myocardial infarction 
were treated with a blocking antibody for the CD11/CD18 integrin receptor. In four hundred patients 
infarct size and mortality were not improved by the treatment 
81.  
However, not all trials have been negative. For example, the data for the use of steroids after 
myocardial infarction are not  clear  at the  moment. Initial  small and  observational  studies  reported an 
increase of left ventricular rupture, i.e. impaired healing, and thus the concept was not thoroughly pursued. 
A recent meta-analysis (n=2,646 patients) revealed decreased mortality in steroid treated patients after 
myocardial infarction but summarized only data from small trials with no large, adequately powered study 
82. 
Furthermore, established drugs  in  the treatment  post  myocardial  infarction  may play a role in 
inflammatory healing. E.g. the early use of mineralocorticoid receptor antagonists reduces mortality after 
myocardial infarction 
83.  
The interpretation of clinical trials with regard to healing and inflammation is difficult due to 
confounding variables like different infarct sizes, gender, age, etc. For example, ageing is associated with a 
decreased ability to control infection (so called immunosenescence), alters the inflammatory response in 
wounds 
84,  and  changes  inflammatory  markers  in  heart  failure 
85.  Whereas  infarct  size  is  a  major 
determinant of remodeling in patients younger than 65 years, in older patients left ventricular remodeling 
can also occur even in the presence of small infarct sizes (PREAMI study 
86) potentially mediated by 
defects in healing.  
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Problematic for new anti-inflammatory approaches is that an intact immune system is necessary 
for  many  protective  pathways  and  adequate  healing  in  the  beginning,  whereas  prolonged  immune 
activation  may  also  activate  unfavourable  signal  cascades  that  drive  disease  progression.  The  major 
challenge of immunosuppressive drugs in the healing phase will be to limit detrimental innate immune 
influences  while  simultaneously  maintaining  and  stimulating  adequate  and  appropriate  innate  immune 
mechanisms. Nevertheless, there are several exciting targets like the coagulation cascade, modulation of 
immune cell function, and the early use of RAS inhibitors to promote healing, improve the inflammatory 
response, and subsequently avoid adverse cardiac remodeling. Thus, further research is necessary to better 
understand the interaction of inflammation and cardiac healing. This will allow us to choose better targets 
at better time points for clinical intervention. 
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Figure Legends 
 
Figure 1. TLR4 in rat, murine and human myocardium.  Primary isolates of adult rat 
ventricular myocytes 24 hr after isolation, stained with a polyclonal antibody targeted to a 
TLR4-specific  epitope  adjacent  to  the  cytoplasmic  TIR  domain  of  hTLR4  (upper  panel). 
Normal  murine  cardiac  muscle  (magnification  200x;  second  panel)  exhibited  diffuse, 
homogeneous myocyte staining. However, cardiac myocytes adjacent to an area of ischemic 
injury  induced  by  coronary  artery  ligation  exhibited  intense  sarcolemmal  TLR4  staining.  
Finally, cardiomyocytes from humans with dilated cardiomyopathy (lower panel) displayed 
intensely stained focal expression of TLR4 (figure reprinted with permission of 
10). 
Figure 2. NF-κB activation in the heart after ischemic injury. In transgenic mice that 
express a luciferase reporter whose transcription is dependent on NF-κB, light generated at 
the site of NF-κB activation within the transgenic mouse is sufficiently intense to be detected 
externally  by  a  light-sensitive  camera  upon  injection  of  luciferin.  Myocardial  infarction 
induced  NF-κB-dependent  in  vivo  luminescence  in  the  heart  of  transgenic  mice  when 
compared  to  sham-operated  mice.  Maximal  NF-κB  activity  was  observed  3  days  after 
myocardial infarction by serial molecular imaging (figure reprinted with permission of 
22). 
Figure 3. MR blockade after myocardial infarction reduced thinning and dilatation of 
the  infarcted  wall.  A,  Typical  sections from infarcted hearts, perfusion-fixed 7  days after 
myocardial  infarction,  scar  thickness,  and  infarct  expansion  index  in  placebo  (PLA)  and 
eplerenone-treated  rats  (EPLE).  Mean±SEM  (n=10  to  14).  P<0.05,  P<0.01  vs  PLA.  B, 
Representative  LV  pressure-volume  loops  measured  in  vivo  with  conductance  catheter  in 
sham-operated rats (sham), and in placebo- (PLA) and eplerenone-treated (EPLE) rats 7 days 
after MI (figure reprinted with permission of 
45).  
Figure  4. Detrimental left  ventricular dilatation following myocardial  infarction and 
inhibition  of  TGF.  Illustrated  are  representative  examples  of  two-dimensional 
echocardiography of mice treated with an anti-TGF-β antibody started either one week before 
(anti-TGF pre MI) or 5 days after (anti-TGF post MI) induction of myocardial infarction. 
Treatment with an anti-TGF-β antibody aggravated left ventricular dilatation (figure reprinted 
with permission of 
77).  
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Figure 4. 
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